Last reviewed · How we verify
CSL889
At a glance
| Generic name | CSL889 |
|---|---|
| Also known as | Hemopexin, human |
| Sponsor | CSL Behring |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis (PHASE2)
- Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |